Here's why Bristol-Myers Squibb's record-breaking $74 billion biotech deal is facing investor backlash

Wall Street analysts questioned whether a combination would produce solutions to each of the two companies' problems.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

BusinessInsider /  🏆 729. in US

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bristol-Myers Squibb to Acquire Celgene for About $74 BillionGlobal biopharmaceutical company Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction for about $74 billion.
Read more »

Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companiesHeavy debt, faltering in 2018, and cracks in the deal: Bristol-Myers Squibb's $74 billion acquisition of Celgene combines 2 troubled companies.
Read more »

Bristol-Myers bulks up cancer portfolio with $74 billion Celgene dealBristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74...
Read more »